Soft tissue sarcoma by Biermann, J. Sybil & Baker, Laurence H.
E D I T O R I A L
See referenced original article on pages 2596–
607, this issue.
Address for reprints: J. Sybil Biermann, M.D., Uni-
versity of Michigan Comprehensive Cancer Center,
1500 East Medical Center Drive, Ann Arbor, MI
48109-0946.
Received March 8, 1999; accepted March 12,
1999.
Soft Tissue Sarcoma
Opening the Door to Advances in Diagnosis and
Treatment
J. Sybil Biermann, M.D.
Laurence H. Baker, D.O.
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
The article by Bergh et al.1 in this issue of Cancer contains impor-tant new insights that improve our understanding of sarcoma and
clearly identify the pathways of future investigations and the future of
sarcoma management.
In this publication, the investigators clearly distinguish a sub-
group of patients with a better prognosis—those younger than 25
years with tumors smaller than 5 cm and no histologic evidence of a
poorly differentiated tumor. The evaluation and treatment of patients
with soft tissue sarcoma has been plagued by the scarcity of the
condition; the variety of presentations in anatomic site, size, and
histologic grade; and the multiplicity of physicians typically involved
in the care of these patients.2 While advances in the survival of
patients with bone sarcoma, an even rarer disease, have been dra-
matic, similar advances in the prognosis and treatment of patients
with soft tissue sarcoma have been more modest. The identification of
subgroups of patients with better or worse prognoses within the
diverse group of patients with soft tissue sarcoma, such as has been
accomplished by these investigators, will help direct clinical trials in
which more aggressive therapies are given to patients with worse
expected outcomes.
Evaluation of soft tissue sarcomas historically relied on light
microscopy only. Controversy existed, indeed, even regarding the
possibility of low grade variants of this malignancy; some pathologists
were of the opinion that all synovial sarcomas were by their very
nature high grade.3 With the identification of certain histologic fea-
tures that are indicative of better prognosis, Bergh et al. help lay to
rest that notion.
However, the future of diagnosis of these tumors will be the
application of contemporary molecular techniques of diagnosis, with
less reliance on pattern recognition. Synovial sarcomas express gene
products that are clearly identifiable by contemporary techniques and
have been shown to correlate with prognosis.4 In multivariate analy-
sis, the type of SYT-SSX fusion transcript was the sole independent
prognostic factor for metastasis free survival in localized tumors.
Patients with tumors positive for SYT-SSX2 have a low risk of early
relapse. Different fusion products generated by cytogenetically iden-
tical translocations (such as X:18 in synovial sarcoma) can have major
clinical correlates, such as the initial demonstration of the Philadel-
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phia chromosome, or BCR-ABLE rearrangement, or
the EWS-FLI1 fusion transcript as a prognostic factor
in the Ewing family of tumors. Future investigations of
the prognoses and treatment of patients with synovial
sarcomas and other soft tissue sarcomas will benefit
from the application of molecular techniques.
Finally, the authors identify treatment outside of a
referral center as an independent risk factor for local
recurrence. Only with the widespread recognition of
the potentially lethal outcome, the necessity of multi-
disciplinary collaboration, and the need to have sar-
comas treated by those thoroughly experienced in
their care will patients be optimally managed.
The future of sarcoma management holds many
opportunities with the identification of subgroups of
patients with favorable prognoses, the application of
contemporary molecular techniques to their diagno-
sis, and the development of centers with both basic
scientists and clinicians who are dedicated to advanc-
ing the understanding of these diseases.
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